Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The MDS Channel

Explore the latest updates, including expert interviews, features, podcasts and e-learning

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Latest Videos The MDS Sessions Conferences Topics Features Podcasts Expert Editorial Board

Welcome to The Myelodysplastic Syndromes (MDS) Channel

Explore all things new and exciting in MDS, with exclusive insights, must-know news, and unique expert perspectives, courtesy of The MDS Channel.

Much research is underway to address the paucity of available options in MDS and many new agents, targets, and treatment approaches are in development or under investigation, such as novel HMA-based combinations, immunotherapies, and other newer agents. With the support of a world-leading Editorial Board, VJHemOnc brings you informative interviews, roundtable discussions, feature articles, and podcasts; a one-stop source for the key MDS news!

Conferences

ASH 2025
SOHO 2025
iwMDS 2025
EHA 2025
EBMT 2025
IBC 2025
5:58
Outcomes of HMA plus venetoclax in HR-MDS: an analysis from the icMDS validate database
Jan Bewersdorf • 16 Dec 2025
1:07
Practice-changing highlights in MDS from ASH 2025: the VERONA trial and triplet combinations
Jennifer Marvin-Peek • 6 Dec 2025
3:57
HMA with venetoclax versus HMA alone in the frontline management of HR-MDS: a real-world analysis
Guru Subramanian Guru Murthy • 15 Dec 2025
1:30
Olutasidenib with co-targeted therapy in R/R IDH1-mutated myeloid malignancies: Phase II trial
Jennifer Marvin-Peek • 6 Dec 2025
View All Videos
10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
7:55
Lower-risk MDS: improving outcomes with luspatercept, imetelstat & new agents
Valeria Santini • 5 Sep 2025
1:45
Precision-T trial: Orca-T vs tacrolimus-methotrexate for GvHD prevention in hematologic malignancies
Rawan Faramand • 4 Sep 2025
1:14
The potential of preventive medicine in MDS
Matteo Della Porta • 5 Sep 2025
View All Videos
15:13
Evolving strategies in clinical trial design for MDS: defining response criteria
Coleman Lindsleyet al. • 28 Jun 2025
7:39
Novel targets in MDS: telomerase inhibition, the SELECT-MDS-1 trial, PK agonists, & more
Amy DeZernet al. • 28 Jun 2025
23:22
iwMDS wrap-up: translating research into practice to optimize patient care
Amer Zeidanet al. • 29 Jun 2025
8:48
Advances made in MDS classification and risk stratification: ongoing work & future perspectives
Luca Laninoet al. • 28 Jun 2025
View All Videos
1:14
Luspatercept versus epoetin alfa in the COMMANDS trial: overall survival after two and a half years
Valeria Santini • 15 Jun 2025
3:59
The use of immunosuppressive therapy in MDS: available agents and areas for further research
Valeria Santini • 15 Jun 2025
1:22
Involving regional centres in the management of MDS and AML to improve access to care
Shaun Fleming • 14 Jun 2025
1:03
Impact of luspatercept on clinical outcomes & HRQoL in transfusion-dependent LR-MDS: COMMANDS trial
Esther Oliva • 14 Jun 2025
View All Videos
0:53
Impact of melphalan dose combined with fludarabine on GI toxicity & GvHD after alloSCT in AML/MDS
Nelli Bejanyan • 1 Apr 2025
2:23
Allogeneic transplantation in elderly patients: insights from Brazilian registry data
Fernando Barroso Duarte • 30 Mar 2025
1:50
Challenges in the diagnosis and management of VEXAS syndrome
Carmelo Gurnari • 1 Apr 2025
2:18
The role of allogeneic transplantation in VEXAS syndrome
Carmelo Gurnari • 1 Apr 2025
View All Videos
1:15
Unmet needs and treatment opportunities for patients with MDS
Matteo Della Porta • 14 Mar 2025
1:23
Challenges and opportunities in early interventional trials for clonal hematopoiesis
Mrinal Patnaik • 14 Mar 2025
1:52
The potential value of AI for individuals with CH: improving risk stratification
Matteo Della Porta • 15 Mar 2025
1:07
MDS in younger patients: the importance of curative approaches & optimizing timing of alloSCT
Matteo Della Porta • 14 Mar 2025
View All Videos

Topics

Immuno-Oncology
Trial Updates
Treatment
Transplantation
Disease Biology
Diagnosis
5:07
Advances in GvHD management presented at ASH 2025
Mohamad Mohty • 5 Dec 2025
11:48
Ask the Expert: Naval Daver answers your AML questions at iwAL 2025
Naval Daver • 21 Sep 2025
1:45
Precision-T trial: Orca-T vs tacrolimus-methotrexate for GvHD prevention in hematologic malignancies
Rawan Faramand • 4 Sep 2025
1:56
Novel concepts in TP53-mutated MDS: from p53 reactivators to immune-based therapies
David Sallman • 4 Sep 2025
View All Videos
1:30
Olutasidenib with co-targeted therapy in R/R IDH1-mutated myeloid malignancies: Phase II trial
Jennifer Marvin-Peek • 6 Dec 2025
2:58
Phase I trial of ONC201 as post-transplant maintenance for AML and MDS
Vijaya Bhatt • 7 Dec 2025
2:27
Updated results from a Phase II trial of elritercept in LR-MDS
Lynette Chee • 8 Dec 2025
1:10
Correlation between treatment-emergent cytopenias and clinical response with imetelstat in LR-MDS
Amer Zeidan • 5 Dec 2025
View All Videos
5:58
Outcomes of HMA plus venetoclax in HR-MDS: an analysis from the icMDS validate database
Jan Bewersdorf • 16 Dec 2025
1:07
Practice-changing highlights in MDS from ASH 2025: the VERONA trial and triplet combinations
Jennifer Marvin-Peek • 6 Dec 2025
3:57
HMA with venetoclax versus HMA alone in the frontline management of HR-MDS: a real-world analysis
Guru Subramanian Guru Murthy • 15 Dec 2025
1:30
Olutasidenib with co-targeted therapy in R/R IDH1-mutated myeloid malignancies: Phase II trial
Jennifer Marvin-Peek • 6 Dec 2025
View All Videos
2:58
Phase I trial of ONC201 as post-transplant maintenance for AML and MDS
Vijaya Bhatt • 7 Dec 2025
1:32
HMA maintenance therapy in TP53-mutated AML and MDS improves outcomes of transplantation
David Sallman • 5 Dec 2025
5:07
Advances in GvHD management presented at ASH 2025
Mohamad Mohty • 5 Dec 2025
17:27
Ask the Expert: Charles Craddock answers your transplantation questions at iwAL 2025
Charles Craddock • 21 Sep 2025
View All Videos
3:53
Improving diagnostic procedures in MDS to avoid invasive bone marrow examination
Moshe Mittelman • 7 Dec 2025
1:10
Correlation between treatment-emergent cytopenias and clinical response with imetelstat in LR-MDS
Amer Zeidan • 5 Dec 2025
10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
6:25
Refining the diagnosis and classification of CMML
Guillermo Montalban-Bravoet al. • 20 Sep 2025
View All Videos
7:37
AI‑driven virtual tumor board enhances precision care in AML: refining AI use in hematology
David Swoboda • 5 Dec 2025
3:53
Improving diagnostic procedures in MDS to avoid invasive bone marrow examination
Moshe Mittelman • 7 Dec 2025
2:53
Key debates in MDS at ASH 2025: diagnosis, pre-disease therapy, & more
Valeria Santini • 5 Dec 2025
1:01
Utilizing molecular data to refine diagnoses in myeloid malignancies with overlapping features
Sanam Loghavi • 6 Dec 2025
View All Videos

thomas-cluzeau
Thomas Cluzeau
MD, PhD
Central University Hospital of Nice
rami-komrokji
Rami Komrokji
MD
Moffitt Cancer Center

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

Silver Supporter

Geron

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

If you are interested in becoming a supporter of The Myelodysplastic Syndromes Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals